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Biochemical Diagnosis of Bile Acid Diarrhea: Prospective
ComparisonWith the 75Seleno-Taurohomocholic Acid Test
Christian Borup, MD1,2, Signe Wildt, MD, PhD1, Jüri Rumessen, MD, DMSci3, Jesper Graff, MD, PhD, DMSci4,
Pierre Nordine Bouchelouche, MD5, Trine Borup Andersen, MD, PhD6, Lars Vinter-Jensen, MD, DMSci7, Anna Zaremba, MD, PhD7,
Søren Peter German Jørgensen, MD, PhD8, Tine Gregersen, MD, PhD9, Camilla Nøjgaard, MD, PhD2, Hans Bording Timm, MD2,
Dominique Rainteau, MD, PhD10, Emilie Gauliard, PhD10 and Lars Kristian Munck, MD, DMSci1
INTRODUCTION: Thediagnosis of bile aciddiarrhea is oftenmissedbecause the availability of the 75seleno-taurohomocholic
acid (SeHCAT) test is limited. We aimed to compare the biomarkers 7a-hydroxy-4-cholesten-3-one (C4)
and fibroblast growth factor 19 (FGF19) with the SeHCAT test.
METHODS: Patients with chronic diarrhea without intestinal resection referred for SeHCAT were prospectively
recruited for this diagnostic accuracy study.Bloodwassampledat fasting andafter a stimulationmealwith
chenodeoxycholic acid. SeHCAT retention £10% defined bile acid diarrhea and >10% defined
miscellaneous diarrhea. Receiver operating characteristics (ROC) were analyzed with SeHCAT as the gold
standard. www.clinicaltrials.gov (NCT03059537).
RESULTS: Patientswithbileaciddiarrhea (n526)hadmeanC4of30ng/mL (95%confidence interval: 19–46) vs8
(7–11;P < 0.001) in themiscellaneous diarrhea group (n5 45). Area under the ROC curve (ROCAUC) for
C4 was 0.83 (0.72–0.93). C4 < 15 ng/mL had 85% (74%–96%) negative predictive value; C4 > 48 ng/
mL had 82% (59%–100%) positive predictive value. Twenty patients had C4 values 15–48 ng/mL, of
whom11/20 had SeHCAT £10%.Median fasting FGF19was 72 pg/mL (interquartile range: 53–146) vs
119 (84–240) (P5 0.004); ROCAUC was 0.71 (0.58–0.83). Stimulated FGF19 responses did not differ
(P5 0.54).
DISCUSSION: We identifiedC4 thresholdswith clinically useful predictive values for the diagnosis of and screening for
bile acid diarrhea in patients with chronic watery diarrhea. Further validation of the cutoff values with
the placebo-controlled effect of sequestrant therapy is warranted (see Visual Abstract, Supplementary
Digital Content 2, http://links.lww.com/AJG/B603).
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/B603 and http://links.lww.com/AJG/B588
Am J Gastroenterol 2020;115:2086–2094. https://doi.org/10.14309/ajg.0000000000000772
INTRODUCTION
Bile acid diarrhea is an often missed cause of chronic watery di-
arrhea, with an estimated prevalence in the general population of
1% (1). It is categorized into types by pathophysiology. Type 1 bile
acid diarrhea is because of impaired bile acid reabsorption from
ileal resection or inflammation. Type 2 is caused by an increased
bile acid synthesis (2), which mostly is idiopathic (3). Type 3 bile
acid diarrhea is because of altered bile acid homeostasis associated
with cholecystectomy, coeliac disease, microscopic colitis, ab-
dominal radiotherapy, and chronic pancreatitis (4).
Thediagnosisofbile aciddiarrheadue tobowel resection is straight
forward (5,6).Unfortunately, patientswith type3andparticularly type
2 bile acid diarrhea often remain undiagnosed or even misdiagnosed
(7), e.g., 32% of patients with diarrhea-predominant irritable bowel
syndrome (IBS-D) have bile acid diarrhea (8). Therefore, increased
awareness and accessible diagnostic options are needed.
Scintigraphic measurements of the 1-week retention in the
enterohepatic circulation of the synthetic bile acid 75seleno-taur-
ohomocholic acid (SeHCAT) is currently the preferred diagnostic
test (9,10). SeHCAT retention#5% (severe bile acid diarrhea) and
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.5% to #10% (moderate) is usually considered diagnostic (8),
whereas SeHCAT retention of .10% to #15% may be an in-
determinate result. Cutoffs ranging from,8% to,11%have found
most use (11). The SeHCAT test is highly sensitive and specific (12),
but it has limited capacity and availability. This delays the diagnosis
of bile acid diarrhea and consequently, the patients may undergo
unnecessary radiological and endoscopic examinations (7). A
readily available test is thereforeneeded (13).Thebile acidprecursor
7a-hydroxy-4-cholesten-3-one (C4) reflects the bile acid synthesis
rate (14), and patients with bile acid diarrhea of any subtype have
elevated C4 blood levels (15–17). C4 and SeHCAT correlate well,
particularly in patients with an ileal resection or a right-sided
hemicolectomy (15,18), andprevious studies have includedmanyof
these patients (15–17). However, recent research recommends that
given an a priori risk of disease.95%, no testing is needed in this
subgroup (19–21). Fibroblast growth factor 19 (FGF19) is released
by enterocytes in the terminal ileum on reabsorption of bile acids
that activate the farnesoid X receptor (22). Fasting FGF19 is in-
versely correlatedwithC4 (23) anddirectlywith SeHCATretention,
but overlap in fasting FGF19 values between patients with bile acid
diarrhea and diarrhea controls impairs its diagnostic usefulness
(24). Our pilot studies indicated that stimulation of FGF19 with a
meal (25) and particularly taken together with the farnesoid X re-
ceptor agonist chenodeoxycholic acid (26) could improve its di-
agnostic capability. Therefore, this study aimed to examine the
diagnostic utility of fasting FGF19, stimulated FGF19, and of C4, in
a prospective cohort of patients referred for SeHCAT.
MATERIALS AND METHODS
Design and patients
This prospective multicenter diagnostic accuracy study recruited
from March 22 to November 3, 2017. Patients aged 18–80 years
referred for SeHCAT were eligible. Exclusion criteria were small
bowel or right hemicolonic resection, inflammatory bowel disease
with the need of systemic steroids within 4 weeks of SeHCAT day
1, sequestrant treatment within 1 week, use of laxatives or anti-
diarrhealmedication except for a stable dose of psylliumhusk and
opioids for pain, cirrhosis, biliary obstruction, frequent biliary
cholics, cholecystitis, pregnancy, breastfeeding, and allergy to
chenodeoxycholic acid or eggs in the test meal.
Our pilot study cutoff values forC4 and stimulated FGF19 (the
90-minute increment and the total area under the curve) did not
support extrapolation to the current study. Therefore, our cutoff
values will be exploratory.
The study was approved by the Ethics Committee for the
ZealandRegion (SJ-546), and data registries were approved by the
Zealand Regional Data Protection Agency (Datatilsynet) (REG-
089-2016). All patients voluntarily gave written informed con-
sent. The Danish Medical Agency approved chenodeoxycholic
acid for study use (EudraCT: 2016-002217-22). The study was
registered on ClinicalTrials.gov (NCT03059537).
Procedures
The SeHCAT test was performed according to the local guidelines.
We defined bile acid diarrhea as SeHCAT retention #10% in the
primary analyses. Retention.10% definedmiscellaneous diarrhea.
The SeHCAT test involves 2 visits 1 week apart at the de-
partment of nuclear medicine. At SeHCAT visit 1, demographic
characteristics, medical history, and concomitant medication were
recorded and thequestionnaires (i) Short form36version2 (27) and
(ii) Short health scale (28) were administered. Stool frequency and
Bristol Stool Formwere registered by a standardized diary for 6 days
between SeHCAT visit 1 and 2. The diary results were assessed
according to the Hjortswang diarrhea activity criteria that define
diarrhea as amean of$3 stools per day and/or amean of$1 liquid
stool per day (29). These criteria have been validated inmicroscopic
colitis (29) and were used in the lack of disease-specific criteria.
Fasting blood samples were collected at SeHCAT visit 2, and the
patients then ingested 1,250 mg chenodeoxycholic acid, which de-
fined t5 0minutes, followed by the test meal consisting of 2 boiled
eggs, 2 slices of toast, and 500mL tap water, as previously described
(26). EDTAplasma samples for FGF19 andC4were taken at fasting
immediately before t5 0, at t5 90, 120, and 150 minutes.
Patient files were subsequently reviewed for final diagnoses
and records of treatment response.
Biochemistry
Fasting blood samples from visit 2 were analyzed locally for total
cholesterol, low- and high-density lipoprotein-cholesterol, triglyc-
erides, and glucose. FGF19 was analyzed with ELISA as previously
reported (R&DSystems,MN) (25,26). C4 and bile acid species were
analyzed with high-performance liquid chromatography tandem
mass spectrometryas previouslydescribed (30,31).Thebiochemical
technicians were blinded from other data.
Power calculation
Wedefined a receiver operating characteristics (ROC) area under
the curve (ROCAUC) of 0.80 as the least acceptable test perfor-
mance and expected 33% of patients to have SeHCAT#10% (8).
With a5 0.01 and b5 0.10, we needed 60 patients. Accounting
for uncertainties, we aimed to include 70 patients.
Statistical analyses
Continuous data are presented as medians with interquartile ranges
(IQRs) or as means with 95% confidence intervals (CIs) and com-
pared accordingly with the Mann-Whitney U test or the Student t
test. Correlations (rs) were analyzed with Spearman rank test. The
cumulated areas under FGF19 curves were calculated with the
trapezoidal rule. Diagnostic values and likelihood ratios were cal-
culated (32,33). The above analyses were performed with IBM SPSS
Statistics version 26. Multivariate logistic regression models were
fitted with R software (version 3.5.2) to predict bile acid diarrhea
(SeHCAT# 10%). Among tentative covariates, C4, FGF19, age, and
mean stool number were significant in univariate testing. A stepwise
backward elimination resulted in the same covariates. Exploring the
plasma bile acid profile, the sum of sulfate conjugated bile acid
species had a high predictive value that was used in a subsequent
model. Two-sided P values, 0.05 were considered significant.
RESULTS
We invited 209 patients and 78 were included (see Figure S1:
STARD flow diagram, Supplementary Digital Content 1, http://
links.lww.com/AJG/B588). Seventy-one patients completed the
protocol, of whom 25 were recruited at Zealand University
Hospital, 22 at Hvidovre University Hospital, 19 at Aalborg
University Hospital, and 5 at Aarhus University Hospital. Bile
acid diarrhea was diagnosed in 36%, 32%, 37%, and 60%,
respectively.
Twenty-six patients (37%) had bile acid diarrhea with SeH-
CAT# 10%. Four patients had type 1 bile acid diarrhea because
of nonresected Crohn’s disease, 15 patients had type 2, and 7
patients had type 3 because of cholecystectomy (n 5 4),
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology The American Journal of GASTROENTEROLOGY
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microscopic colitis (n5 1), coeliac disease (n5 1), or pancreatic
insufficiency (n 5 1). The final diagnoses in the miscellaneous
diarrhea group were IBS (n5 16), functional diarrhea (n5 11),
indeterminate bile acid diarrhea (SeHCAT 10.1–15%) (n5 11),
ulcerative colitis (n5 3), Crohns’ disease (n5 2), constipation
diarrhea (n 5 1), and pancreatic insufficiency (n 5 1). The
patients with bile acid diarrhea were younger and had more
frequent bowel movements, and all but one fulfilled the
Hjortswang diarrhea activity criteria. The symptoms reported
by the 2 groups were similar (Table 1).
7a-hydroxy-4-cholesten-3-one
MeanC4was higher in patientswith bile acid diarrhea (30 ng/mL, 95%
CI: 19–46) than in patientswithmiscellaneous diarrhea (8 ng/mL, 95%
CI: 7–11; P, 0.0001) (Table 2). C4 correlated inversely with SeHCAT
(rs520.64; n571,P,0.0001) (see Figure S2, SupplementaryDigital
Table 1. Patient characteristics
SeHCAT > 10% SeHCAT £ 10%
Miscellaneous diarrhea Bile acid diarrhea
n 5 45
All types Type 1 Type 2 Type 3
n 5 26 n 5 4 n 5 15 n 5 7
Demographic characteristics
Sex, female 27 (60%) 17 (65%) 2 (50%) 10 (67%) 5 (71%)
Age, yr 55 (45–64)a 45 (34–49)a 39 (37–44) 46 (27–51) 46 (41–54)
Body mass index, (kg/m2) 26 (23–31) 30 (25–36) 30 (28–34) 30 (22–39) 30 (29–46)
Current smoking 13 (29%) 5 (19%) 2 (50%) 2 (13%) 1 (14%)
Diary results
No. of stools per day 3 (2–4)a 4 (3–5)a 5 (4–5) 3 (3–4) 5 (4–6)
Bristol Stool Form Scale per stool 6 (5–6) 6 (6–6) 6 (6–7) 6 (5–6) 6 (6–6)
Mean number of stools $3.0 per day 23 (51%) 20 (77%) 4 (100%) 9 (60%) 7 (100%)
Mean Bristol type 6 and 7 per day $ 1.0 32 (71%) 24 (92%) 4 (100%) 14 (93%) 6 (86%)
Hjortswang diarrhea criteria, positive 34 (76%) 25 (96%) 4 (100%) 14 (93%) 7 (100%)
Reported symptoms
Urgency 43 (98%)b 26 (100%) 3 (75%) 15 (100%) 6 (100%)
Fecal incontinence 32 (72%)b 21 (81%) 4 (100%) 12 (80%) 4 (67%)
Nocturnal diarrhea 22 (50%)b 15 (58%) 3 (75%) 8 (53%) 4 (67%)
Abdominal pain 31 (72%)c 15 (60%)d 3 (75%) 8 (57%)e 4 (67%)
Bloating 40 (89%) 21 (84%)d 3 (75%) 12 (80%) 4 (80%)f
Diarrhea duration
1–2 yr 9 (20%)b 4 (16%)d 1 (25%) 3 (21%)e 0 (0%)
.2 yr 19 (43%)b 17 (68%)d 2 (50%) 10 (71%)e 5 (71%)
Patient chart data
Response to sequestrant treatment N/A
Good 18 (69%) 3 (75%) 9 (60%) 6 (86%)
Insufficient 4 (15%) 1 (25%) 3 (20%) 1 (14%)
Intolerant 2 (8%) 0 (0%) 2 (13%) 0 (0%)
Not recorded in the patient file 2 (8%) 0 (0%) 1 (7%) 0 (0%)
Ultimate sequestrant treatment N/A
Colestyramine 17 (65%) 3 (75%) 9 (60%) 5 (71%)
Colesevelam 3 (12%) 0 (0%) 2 (13%) 1 (14%)
None 6 (23%) 1 (25%) 4 (27%) 1 (14%)
Demographic characteristics, diary stool registration, and reported subjective symptoms registered at study visit 1. Treatment response and ultimate sequestrant treatment
were obtained in a subsequent review of patient files. SeHCATretention# 10%defined bile acid diarrhea; data from these patients are also shown divided by the 3 subtypes
of bile acid diarrhea. Categorical data are shown as n (%) and continuous data as median with interquartile range.
75SeHCAT, 75-seleno tauro-homocholic acid retention test; N/A, not applicable.
aMann-Whitney U test, P, 0.05. Unless given in the top row, the denominator was, b: 44, c: 43, d: 25, e: 14, f: 5.
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Content 1, http://links.lww.com/AJG/B588) and with FGF19
(rs 5 20.33; n 5 71, P 5 0.005). ROC analysis of fasting C4
and SeHCAT retention# 10% gave a ROCAUC of 0.83 (0.72–0.93;
P , 0.0001). C4 ,15 ng/mL had an 85% (74%–96%) negative
predictive value (NPV) to exclude, andC4. 48ng/mLhad an 82%
(59%–100%) positive predictive value (PPV) to diagnose bile acid
diarrhea. Twenty patients had C4 of 15–48 ng/mL, 11 (55%) of
these had SeHCAT# 10% (Figure 1A). The cutoffC4. 30 ng/mL
had a PPV of 78% (59%–97%) and NPV of 77% (66%–89%)
(Table 3). See Table S2, Supplementary Digital Content 1, http://
links.lww.com/AJG/B588 for more cutoff values.
Four patients with SeHCAT retention of 13, 16, 18, and 23%
had high values of C4 (range 40–58 ng/mL) (Figure 1A andFigure
S1, Supplementary Digital Content 1, http://links.lww.com/AJG/
B588). One of these had microscopic colitis and one had ulcer-
ative colitis. Six patients with SeHCAT# 10% had low C4 values
(,15 ng/mL).One of these used statin for hypercholesterolaemia.
C4 was unaffected by controlling for cholesterol.
FGF19
Median fasting FGF19 was lower in patients with bile acid di-
arrhea (72, IQR 53–146 pg/mL) than in patients with mis-
cellaneous diarrhea (119, IQR 84–240 pg/mL; P5 0.004). There
was no difference in FGF19 stimulated with a meal plus che-
nodeoxycholic acid for the 90-minute increment in FGF19, the
total area under the FGF19 curves (FGF19AUC), or FGF19 at 120
or 150 minutes (Table 2). Similarly, low fasting FGF19 corre-
lated with low SeHCAT retention (rs5 0.31; P5 0.01). whereas
the stimulated total FGF19AUC and SeHCAT did not (rs5 0.07;
P 5 0.55).
The ROC analysis of fasting FGF19 with SeHCAT# 10% gave
ROCAUCof 0.71 (95%CI: 0.58–0.83;P50.004). FGF19,60pg/mL
had a 75% (51%–100%) PPV for diagnosis and had 78% overall
diagnostic accuracy; FGF19 $204 pg/mL had 88% (73%–100%)
NPV to exclude moderate to severe bile acid diarrhea (Table 3).
Forty-twopatients had FGF19of 60–204 pg/mL, ofwhom15 (36%)
had SeHCAT# 10%. See Table S3, Supplementary Digital Content
1, http://links.lww.com/AJG/B588 for more cutoff values.
Plasma bile acids
The patients with bile acid diarrhea had less secondary bile acids
(0.58 mM [IQR: 0.20–1.22] vs 1.04 mM [0.62–1.53]; P 5 0.008,
Bonferroni corrected not significant), significantly less sulfate con-
jugated bile acid species (0.16 mM [0.05–0.36] vs 0.36 mM
[0.23–0.65]; P 5 0.001), and less lithocholic acid species (0.16 mM
[0.03–0.36] vs 0.36 mM [0.21–0.63]; P 5 0.001) (see Table S1,
Supplementary Digital Content 1, http://links.lww.com/AJG/B588).
Exploratory predictive modeling
An exploratory logistic regressionmodel to predict SeHCAT# 10%
improved the ROCAUC to 0.88 (0.79–0.96) by controlling the loga-
rithmofC4 for age andmean stools per day. Including the logarithm
of FGF19 increased the ROCAUC to 0.91 (0.84–0.98) (Table 4). The
covariates sex, bodymass index, Bristol Stool Form, any cholesterol,
or plasma triglycerides did not improve the model. Further explor-
atory analysis showed that a model with C4, age, and the sum of
sulfate conjugated bile acid species in plasma achievedROCAUC 0.91
(0.83–0.98). See supplementary material (Supplementary Digital
Content 1, http://links.lww.com/AJG/B588) for model equations.
Patient chart treatment response
Subsequent chart review of observational treatment response
was available for most patients with SeHCAT ,15% according
to local treatment practice. Treatment response was reported by
18 of 26 patients with SeHCAT# 10%, by 8 of 11 patients with
C4. 48 ng/mL, and of 5 of 12 patients with FGF19,60 pg/mL
(Table 5).
Table 2. Fasting C4, fasting, and stimulated FGF19 specified by SeHCAT subgroups
SeHCAT
Retention
C4
Mean (95% CI)
FGF19
Median (IQR)
0 min 0 min 90 min 120 min 150 min Δ90–0 Total AUC
#10%
n 5 26
30b
(19–46)
72a
(53–146)
140
(81–191)
233
(142–294)
239
(122–356)
36
(214 to 104)
23,740
(16,339–35,781)
.10%
n 5 45
8b
(7–11)
119a
(84–240)
144
(85–230)
198
(139–371)
261
(116–440)
10
(228 to 51)
28,770
(17,052–35,834)
#5 %
n 5 16
40
(26–61)
67
(52–172)
116
(93–185)
233
(186–294)
244
(178–356)
22
(222 to 63)
23,991
(16,339–29,383)
.5 to #10%
n 5 10
18
(7–49)
79
(53–134)
152
(53–318)
217
(74–552)
162
(99–649)
92
(19 to 184)
22,117
(9,045–44,667)
.10 to#15%
n 5 12
13
(8–19)
150
(96–223)
159
(107–452)
249
(161–455)
291
(139–464)
26
(244 to 213)
29,552
(20,332–56,614)
.15%
n 5 33
7
(5–10)
112
(82–240)
140
(84–204)
175
(124–371)
261
(96–440)
8
(228 to 38)
28,770
(14,308–34,232)
Mean7a-hydroxy-4-cholesten-3-one (C4) inng/mLwith95%CI;medianFGF19 inpg/mLwith IQRs.BothC4andFGF19weremeasuredat fastingbefore thestimulation: ingestion
of thestudymeal plus1,250chenodeoxycholicacid (t50min). Subsequentmeasurements for FGF19wereperformedafter 90,120, and150minutes. The calculated increment
in FGF19 from fasting to t5 90 minutes is shown (Δ90–0). The total area under the FGF19 curve (AUC) was calculated with the trapezoidal rule (pg/ml ∙min).
AUC, area under ROC curve; CI, confidence interval; FGF19, fibroblast growth factor 19; IQR, interquartile range; 75SeHCAT, 75-seleno tauro-homocholic acid retention test.
aMann-Whitney U test; P5 0.004.
bStudent t test; P, 0.00001.
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Adverse events
There were 2 serious adverse events deemed nonrelated to cheno-
deoxycholic acid: one patient with pneumonia and one patient with
acute norovirus gastroenteritis. Common side effects were transient
diarrhea (28% of the participants) and abdominal pain (24%).
DISCUSSION
This prospective diagnostic accuracy study compared FGF19 and
C4 for diagnosing bile acid diarrhea with SeHCAT# 10% as the
gold standard test. We verify that C4 has potential clinical value
both for screening and diagnosis of bile acid diarrhea, and we
confirm that the diagnostic performance is high also in patients
without intestinal resection. C4 ,15 ng/mL had 85% NPV and
C4 . 48 ng/mL had 82% PPV. Exploratory logistic regression
showed that the accuracy of C4might be improved by controlling
for mean stool number, age, and FGF19.
Our diagnostic performance of fasting C4 was slightly lower than
that in a previous comparable study (15) that reported an 87% sen-
sitivity and 86% sensitivity for C4 . 30 ng/mL compared with
SeHCAT. However, 12 of these 46 patients had bile acid diarrhea
because of ileal resection. Recent recommendations are not to test
these patients with .95% a priori risk of disease (19–21), so we
excluded such patients to focus on a populationwith an intermediate
prevalence of the disease, such as the 32% prevalence of bile acid
diarrhea in IBS-D (8). This likely explains the difference in test per-
formance. Higher diagnostic cutoffs at approximately 48 ng/mL,
which is the upper normal limit (16), have been used in patients with
chronic diarrhea of various aetiologies (16) and patientswithCrohn’s
disease (34,35). We substantiate the use of this cutoff with an 82%
PPV in our population. Values,48 ng/mL have also been suggested
for screening (36)but onlyhad72%NPVinourpopulation (Table 3),
whereC4,15ng/mLwas a better cutoff, with 85%NPV.Combining
C4 . 48 ng/mL for diagnosis and C4 ,15 ng/mL for screening
correctly categorized 43 of 51patients. Twenty patients hadC4 values
in the rangeof15–48ng/mL,ofwhom11 (55%)hadSeHCAT# 10%
(Figure 1). To avoidmissing the diagnosis, patientswith intermediate
C4 values could be given an empirical treatment. However, the in-
terpretation of this is difficult and recent guidelines do not recom-
mend empirical treatment for primary diagnosis (37,38).Our present
data on treatment outcome is retrospective and lack and lack a
control group;however, thedata suggest thatmostpatientswithC4.
48 ng/mL have a beneficial response. C4 is of potential clinical value,
Figure 1. (a) The distribution of 7a-hydroxy-4-cholesten-3-one (C4) divided by 75-seleno-taurohomocholic acid (SeHCAT) retention in 71 patients.
Retention# 10% defined bile acid diarrhea (n5 26). A gray zone of C4 values from 15 to 48 ng/mL is shown. (b) Receiver operator characteristics (ROC)
curves for C4. The red line shows theROCanalysis of an exploratory logistic regressionmodel controlling for C4, FGF19, age, and themeannumber of stools
to predict SeHCAT#10%. (c) Thedistribution of fibroblast growth factor 19 (FGF19) dividedby SeHCATretention; FGF19 from60 to 204pg/mL is shownas
a gray zone. (d) ROC curves for FGF19.
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Table 3. Receiver operating characteristics for C4 and FGF19 in SeHCAT subgroups
SeHCAT retention ROCAUC
Pos.
cutoff Sensitivity, % Specificity, % PPV, % NPV, %
Positive
likelihood ratio
Negative
likelihood ratio
Diagnostic
accuracy (%)
Fasting C4
#5% (n5 16) 0.87
(0.78–0.95)
.15 94 (82–100) 71 (59–83) 48 (31–66) 98 (93–100) 3.2 (2.1–5.0) 0.1 (0.01–0.6) 76
.30 69 (46–91) 87 (78–96) 61 (39–84) 91 (83–98) 5.4 (2.5–11.6) 0.4 (0.2–0.7) 83
.48 38 (14–61) 91 (83–99) 55 (25–84) 83 (74–93) 4.1 (1.4–11.8) 0.7 (0.5–1.0) 79
#10% (n5 26) 0.83
(0.72–0.93)
.15 77 (61–93) 76 (63–88) 65 (48–81) 85 (74–96) 3.1 (1.8–5.5) 0.3 (0.1–0.6) 76
.30 54 (35–73) 91 (82–99) 78 (59–97) 77 (66–89) 6.1 (2.2–16.4) 0.5 (0.3–0.8) 78
.48 35 (16–53) 96 (90–100) 82 (59–100) 72 (60–83) 7.8 (1.8–33) 0.7 (0.5–0.9) 73
#15% (n5 38) 0.81
(0.70–0.91)
.15 66 (51–81) 82 (69–95) 81 (67–95) 68 (53–82) 3.6 (1.7–7.7) 0.4 (0.3–0.7) 73
.30 39 (24–55) 91 (81–100) 83 (66–100) 57 (43–70) 4.3 (1.4–13.7) 0.7 (0.5–0.9) 63
.48 24 (10–37) 94 (86–100) 82 (59–100) 52 (39–64) 3.9 (0.9–16.8) 0.8 (0.7–1.0) 56
Fasting FGF19
#5% (n5 16) 0.64
(0.47–0.81)
,60 38 (14–61) 89 (81–97) 50 (22–78) 83 (73–93) 3.4 (1.3–9.2) 0.7 (0.5–1.0) 78
,204 88 (71–100) 27 (15–39) 26 (14–38) 88 (73–100) 1.2 (0.9–1.5) 0.5 (0.1–1.8) 41
#10% (n5 26) 0.71
(0.58–0.83)
,60 35 (16–53) 93 (86–100) 75 (51–100) 71 (60–83) 5.2 (1.5–17.5) 0.7 (0.5–0.9) 72
,204 92 (82–100) 33 (20–47) 44 (31–58) 88 (73–100) 1.4 (1.1–1.8) 0.2 (0.1–0.9) 41
#15% (n5 38) 0.62
(0.49–0.76)
,60 26 (12–40) 93 (86–100) 83 (62–100) 53 (40–65) 4.3 (1.0–18) 0.8 (0.6–0.97) 58
,204 87 (76–98) 36 (20–53) 61 (48–74) 71 (49–92) 1.3 (1.0–1.8) 0.4 (0.1–0.9) 63
ROC for 7a-hydroxy-4-cholesten-3-one (C4) with cutoffs in ng/mL and FGF19 with cutoffs in pg/mL, both with SeHCAT retention test as gold standard. Bile acid diarrhea is defined by SeHCAT retention values:#5% severe; 5 to
#10% moderate, and 10 to #15% indeterminate. Brackets show 95% confidence intervals.
FGF19, fibroblast growth factor 19; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristics; ROCAUC, area under the ROC curve; SeHCAT, 75-seleno-taurohomocholic acid.
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especially where SeHCAT is unavailable. BecauseC4 ismeasured at a
single time point, it is less robust than the 1-week SeHCAT exami-
nation that quantifies the bile acids loss over numerous enterohepatic
cycles. However, the symptoms of bile acid diarrhea are generally
persistent (39,40) and replicate C4measurements are consistent (36).
More extensive testing for bile acid diarrhea is needed to avoid
missing the diagnosis (7,8). Early testing of patients with chronic
waterydiarrhea couldbe considered, andbecauseC4 ismuchcheaper
than SeHCAT, this is feasible. Testing would also be relevant in
patientswith functionaldiarrheaor IBS-D, ashasbeenrecommended
in the 2019 AGA clinical practice guidelines (41).
Different purposes and cutoffs have been suggested for fasting
FGF19. It is amarker of ileal resection and inflammation (42), and
a study found fasting FGF19 to have a ROCAUC of 0.74 and
suggested a 145 pg/mL cutoff for bile acid diarrhea (24). Later
studies have used FGF19 for diagnosis with a cutoff# 61.7 pg/mL
in IBS-D and functional diarrhea (36), and in patients with
Crohn’s disease, a similar cutoff ,60 pg/mL has been used
(34,35). Our ROCAUC of 0.71 replicates the previous findings, and
we substantiate using the diagnostic cutoff of FGF19,60 pg/mL
that in our population had 75% PPV. Similarly, FGF19. 204 pg/
mL had a high NPV of 88%. As reported in previous studies, we
found a large overlap in FGF19 between diarrhea controls and bile
acid diarrhea. In fact, 59% of our patients had FGF19 values
between 60 and 204 pg/mL, so the performance of FGF19 is low.
In contrast to our pilot comparison of patients with severe type
2 bile acid diarrhea and healthy volunteers (26), stimulation with
chenodeoxycholic acid and a meal did not improve the diagnostic
characteristics of FGF19 in this study. Others have shown that
incubation of ileal biopsies with chenodeoxycholic acid caused a
16-fold FGF19 increase in biopsies from patients with bile acid
diarrhea and a 182-fold increase in biopsies from patients with
idiopathic diarrhea (3). However, our 26 patients with bile acid
diarrhea had a normalmagnitude and temporal increase in FGF19
(Table 2), resembling the response inhealthy volunteers (26,43,44).
Our explorative logistic regression models indicate how the
diagnostic precision of C4 might be improved. Controlling for age
and number of stools increase the ROCAUCof C4 from0.81 to 0.88;
adding FGF19 gave ROCAUC of 0.91 (Table 4). Our patients with
bile acid diarrhea had less sulfate conjugated bile acids in plasma
(Suppl. Table S1). The intestinal loss of bile acids in patients with
bile acid diarrheamay result in fewer sulfate-conjugated species for
urinary excretion (31,45), and this together with age and C4 ach-
ievedROCAUCof0.91. The exploratorymodels needvalidation and
should include other factors such as cholecystectomy, abdominal
radiotherapy, inflammatory bowel disease, and ileal resection
(21,37).
We recruited patients at 4 sites which could have contributed to
heterogeneity, but the prevalence of bile acid diarrhea at the centers
was similar. Our sample size was sufficient to confirm the di-
agnostic characteristics of C4 and fasting FGF19. Nevertheless, the
diagnostic options need validation with the placebo-controlled
effect of sequestrant treatment.
In conclusion,wehave identifiedC4valueswith clinically useful
predictive values for the diagnosis of and screening for bile acid
diarrhea in a prospective population of patients without previous
intestinal resection investigated with SeHCAT. Implementation of
C4 testing in patients with chronic watery diarrhea could facilitate
easier and earlier identification of patients with bile acid diarrhea.
We have suggested ways to optimize the accuracy and clinical
utilization of a C4-based test. Validation of the diagnostic modal-
ities and cutoff values with the placebo-controlled effect of
sequestrant therapy is warranted to predict beneficial treatment
response.
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Table 5. Observational treatment response from chart review
Patient chart treatment response
Yes No Intolerant Missing data
SeHCAT retention (%)
#5 12 3 1 1
.5 to #10 6 0 1 2
.10 to #15 7 3 1 1
.15 1 3 1 28
C4 (ng/mL)
,15 9 5 1 25
15 to 30 7 1 1 4
.30 to 48 2 2 1 2
.48 8 1 1 1
FGF19 (pg/mL)
,60 5 3 0 4
60 to 204 18 5 4 15
.204 3 1 0 13
Treatment response from chart review. Treatment was initiated and effect
evaluated by the patient’s tending physician.
FGF19, fibroblast growth factor 19; SeHCAT, 75-seleno-taurohomocholic acid.
Table 4. An exploratory predictive logistic regression model
Covariate OR 95% CI P Estimate SE
C4, 50% increase 1.7 1.3–2.3 ,0.001 3.2 0.04
Age, 5 year increase 0.7 0.5–0.9 0.01 20.36 0.14
Stools/d, mean increase of 1 1.5 1.1–2.3 0.03 0.43 0.19
FGF19, 50% increase 0.6 0.4–0.9 0.04 20.47 0.23
ROC 0.91 (95% CI: 0.84–0.98)
Exploratory multivariate logistic regression model to predict bile acid diarrhea
defined as SeHCATretention#10%. Univariate testing was significant for each
covariate (.10% vs # 10%). Both C4 and FGF19 have undergone a
logarithmic transformation. The model has an intercept of 25.4, with estimate
3.2 and SE of 3.2. A model index cutoff . 0.32 has 88% sensitivity, 84%
specificity, and a likelihood ratio of 5.7. An index cutoff . 0.7 has 65%
sensitivity, 96% specificity, and a positive likelihood ratio of 16.
OR, odds ratio; CI, confidence interval; FGF19, fibroblast growth factor 19;ROC,
receiver operating characteristics; SE, standard error; SeHCAT, 75-seleno-
taurohomocholic acid.
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Study Highlights
WHAT IS KNOWN
3 One-third of patients with IBS-D have bile acid diarrhea.
3 Access to the 75SeHCAT acid test is limited.
3 Bile acid diarrhea is treatable with sequestrant therapy.
WHAT IS NEW HERE
3 Biochemical screening for and diagnosis of bile acid diarrhea
is feasible.
3 7a-hydroxy-4-cholesten-3-one (C4) test was the superior
biochemical test.
3 Validity was confirmed in patients without intestinal resection.
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